Intec Pharma — Investor Presentation (January 2019)
32 slides from Intec Pharma's investor presentation, Jan 7, 2019
Slide 1: Corporate Presentation January 2019
Corporate Presentation Nasdaq: NTEC January 2019 Corporate Presentation
Slide 2: Forward-looking statements
This presentation by Intec Pharma Ltd. (referred to as “we” or “our”) contains forward - looking statements about our expectations , beliefs and intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategi es, plans and pro
Slide 3: Investment Highlights
Investment Highlights Parkinson’s Program Phase 3 Unencumbered WW rights Topline data expected in mid - 2019 AP Cannabinoids (CBD, THC) Various indications in Phase 1 Proprietary drug evaluation Proprietary oral delivery system of drugs on film The Accordion Pill™ (AP) Future potential value drivers
Slide 4: The Accordion Pill: A new platform for oral drug delivery
The Accordion Pill: A new platform for oral drug delivery AP capsule dissolves and outer layers facilitate unfolding mechanism of films Layers comprise an inner, controlled release drug - containing layer, and immediate release layer(s) for multiple drug release profiles and/or fixed - dose combinat
Slide 5: The Accordion Pill (AP) Platform Technology
Each film layer designed as different delivery system; Mix and match multiple layers, multiple drugs Unique Advantages : – Enhanced gastric retention – Improved PK – High drug loading – Fix dose combination – Multiple drug release profiles – Tested in multiple clinical trials – PK and efficacy studi
Slide 6: Business Strategy
Business Strategy Partner’s Proprietary Drugs In Development Partner’s Lifecycle Management In - house Development Of Existing Drugs 505(b)2 6
Slide 7: Accordion Pill Development Pipeline
Product Candidate Research Phase 1 Phase 2 Phase 3 Status AP - CD/LD For treatment of severe symptoms in advanced Parkinson’s disease Top - line data expected mid - 2019 AP - CD/LD PK study in 500mg TID dose (3x per day) Study results expected January 2019 AP - THC Cannabinoid treatments various pai
Slide 8: Parkinson's Disease Phase 3 Program AP-CD/LD
• Unencumbered world wide rights • De - risked asset ‒ Levodopa well characterized – the Gold Standard for PD ‒ Strongly supportive Phase 2 efficacy and PK data ‒ Wealth of preclinical and clinical safety data • Large unmet medical need ‒ Physicians still struggle to manage motor fluctuations • Bill
Slide 9: Levodopa PK Is Important In Parkinson's
Levodopa PK Is Important In Parkinson’s Stabilizing LD plasma levels becomes a major factor for improving anti - parkinsonian control in Advanced PD Challenge in improving LD PK 0 5 10 15 years Early Treated PD stable Advanced PD/Motor Fluctuations *C.W. Olanow, et al. , Nature Clinical Practice Neu
Slide 10: Phase II AP-CD/LD Results: More Stable PK
• Prolonged absorption • Decreased peak to trough ratio • Significantly higher morning plasma levels Significantly More Stable PK Achieved by AP - CD/LD Phase II AP - CD/LD Results AP - CD/LD enables steady therapeutic levodopa levels 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 0.0 4.0 8.0 12.0
Slide 11: Phase II AP-CD/LD Results: Reduced off time and dyskinesia
Phase II AP - CD/LD Results Significant reduction in daily off time and dyskinesia Significantly Reduced TSD Significantly Reduced Off Time Off Time (Hours) Following 3 Weeks Treatment 45% reduction p<0.0001 ON with Troublesome Dyskinesia Time (Hours) Following 3 Weeks Treatment n=18 AP - CD/LD 50/5
Slide 12: AP-CD/LD Phase III Trial Design
AP - CD/LD Phase III Trial Design ~ 80+ Clinical sites across 10 countries 6 Weeks 13 Weeks 2 Weeks 50 / 400 , 50 / 500 BID, TID Open label N= 462 Double Blind 12 Months 6 Weeks Stabilization on Sinemet® AP - CD/LD Conversion Enrollment Committee Review Treatment Period Sinemet + AP - CD/LD dummy Tr
Slide 13: Parkinson's Disease Treatment Landscape
Parkinson’s Disease Treatment Landscape Baseline Therapies Adjuvant and Rescue Therapies End Stage Therapies • LD the most effective anti - Parkinsonian agent available • Virtually all patients respond to LD • > 90 % of patients develop LD - induced motor complications Sublingual Apomorphine – PDUFA
Slide 14: AP-CD/LD: A Better, Simpler Solution
AP - CD/LD: A Better, Simpler Solution Today’s Baseline Therapy IR CD/LD (Gold Standard) Rytary (<10% Mkt Share) • Short - acting/highly pulsatile • Increased issues with OFF time and dyskinesia • Up to 10 doses per day • Highly variable absorption • Increased issues with OFF time and dyskinesia • 3
Slide 15: Non-compliance Results in Increased Motor Fluctuations and Healthcare Costs
Non - compliance Results in Increased Motor Fluctuations, Medical Problems & Healthcare Costs Source: Medication Non - adherence in PD. Fleisher, et. al., Curr Neurol Neurosci Rep , 2013; Drug Adherence in PD. Leopold, et. al., Jn of Movement Disorders , v19, 2004 • Up to 3 + PD medications on any g
Slide 16: US Market Opportunity
$ 300 MM - $ 1 BN+ US Market Opportunity Potential Game Changer • Easier Titration • Better Compliance • Reduced Pill Burden Improvement in OFF - Time (Hours) Market Potential Scenario Current Therapies Incremental Off - Time Improvement Significant Off - Time Improvement Sales Forecasting Assumptio
Slide 17: Pre-Commercial Activities
Pre - Commercial Activities Market Access Market Research Regulatory Rx Packaging Manufacturing 17
Slide 18: Commercial Scale Manufacturing
Commercial Scale Manufacturing • Partnership with LTS for commercial scale production of AP - CD/LD • Leading global formulation and film technology manufacturer • Commissioning and factory testing underway • Commercial scale machine delivered in 2H18 • Validation, bridging and stability studies to
Slide 19: Cannabis and Pain Relief
Medical cannabis market has growing acceptance and regulatory path forward Cannabis and Pain Relief • Cannabis has been used around the world for centuries • Starting with Chinese around 2900 B.C., many civilizations used cannabis for variety of conditions, from joint pain and muscle spasms to gout
Slide 20: AP-CBD/THC
AP - CBD/THC • AP - CBD/THC contains – Cannabidiol (CBD) – 9 - Tetrahydrocannabinol (THC) • Being evaluated for various pain indications Challenges : • Hydrophobic • Insoluble • Poorly bioavailable Current Treatment Drawbacks: • Short duration of effect • Delayed onset • Dose variability • Adverse e
Slide 21: Phase I Topline Results with AP-CBD/THC
Single - center, single - dose, randomized, 3 - way crossover study compared PK, safety and tolerability of AP - CBD/THC with Sativex ® in 21 normal healthy volunteers • Accordion Pill delivered CBD and THC with significant improvements in exposure compared with Sativex ‒ Increased exposure of CBD b
Slide 22: Accordion Pill CBD and THC Next Steps
Accordion Pill CBD and THC Next Steps • Evaluate THC alone and CBD alone for pain states • Phase 1 PK study of AP - THC is ongoing and AP - CBD to initiate in 1Q19 • Advance best candidate(s) to Phase 2a pain study in 2H19 Exploring the individual components will provide additional indications to pu
Slide 23: Partners' Proprietary Drugs in Development: Novartis Example
Partners’ Proprietary Drugs in Development Novartis Example • Explore using the Accordion Pill platform for a proprietary Novartis compound • Developing Accordion Pill to meet Novartis criteria — Achieved technical specifications in vitro (YE18) — Initiate Phase 1 PK study (1H19) • Novartis has the
Slide 24: Potential for Enhancing Delivery and Retention
Potential for Enhancing Delivery and Retention • Many drugs fail to reach the market due to poor bioavailability • ~40% of top 200 major market drugs are poorly soluble (BCS Class II or Class IV (1) ) • Historically, ~90% of new chemical entities in development, were either BCS Class II or Class IV
Slide 25: Poorly Soluble Proof of Concept
Poorly Soluble Proof of Concept: Commercial “X” Accordion Pill with Poorly Soluble Drugs: PK Clinical Study • PK issues of drug X include only 30 % absorption and lack of dose proportionality above approved marketed dose (X mg) • AP significantly extended absorption phase of drug • Approximately 100
Slide 26: IP Overview
IP Overview • Platform IP – Various Accordion Pill dosage forms – Latest U.S. patent expires in 2029 • Manufacturing IP – Methods for making/folding gastro - retentive drug delivery system – U.S. patent expires in 2028 • Specific formulation IP – For example, U.S. patent of AP - CD/LD expires in 202
Slide 27: Capital Structure and Cash Position
Capital Structure and Cash Position Institutional Holders* U.S. • 683 Capital Management • Adage Capital • Caxton Asset Management • DAFNA Capital Management • Kearny Venture Partners • ProSight Capital Management • Sectoral Asset Management • venBio Select Israel • Dexcel Pharma Technologies • Hare
Slide 28: Experienced Management Team
Experienced Management team Jeffrey A. Meckler Vice Chairman & CEO Nadav Navon Chief Operating Officer Nir Sassi Chief Financial Officer Walt Linscott Chief Business Officer R. Michael Gendreau, MD Chief Medical Officer 28
Slide 29: Experienced Board of Directors
Experienced Board of Directors John W. Kozarich, Ph.D. Chairman Gil Bianco Director Hila Karah Director Anthony J. Maddaluna Director Roger J. Pomerantz, M.D. Director Isaac Silberman Director Sulam Financial Holdings Company W. Brad Hayes Director 29
Slide 30: Accomplishments and Milestones in 2019
Accomplishments and Milestones in 2019 Recent Upcoming x Completed enrollment of Phase 3 AP - CD/LD trial x >90% of eligible patients from Ph 3 trial AP - CD/LD entered the Open Label Extension study x Delivered the commercial manufacturing equipment to LTS x Initiated PK study of AP - THC x Met the
Slide 31: Investment Highlights
Investment Highlights Parkinson’s Program Phase 3 Unencumbered world wide rights AP Cannabinoids (CBD, THC) Various indications in Phase 1 Proprietary drug evaluation Proprietary oral delivery system of drugs on film The Accordion Pill™ (AP) Future potential value drivers Potential for multiple coll
Slide 32: Thank you
Thank you www.intecpharma.com